Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Non-Current Liabilities: 2019-2020

Historic Total Non-Current Liabilities for Keros Therapeutics (KROS) over the last 2 years, with Dec 2020 value amounting to $7.7 million.

  • Keros Therapeutics' Total Non-Current Liabilities rose 54.74% to $11.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $11.5 million, marking a year-over-year increase of 54.74%. This contributed to the annual value of $7.7 million for FY2020, which is 25.93% down from last year.
  • Keros Therapeutics' Total Non-Current Liabilities amounted to $7.7 million in FY2020, which was down 25.93% from $10.3 million recorded in FY2019.
  • Keros Therapeutics' Total Non-Current Liabilities' 5-year high stood at $10.3 million during FY2019, with a 5-year trough of $7.7 million in FY2020.
  • Moreover, its 2-year median value for Total Non-Current Liabilities was $9.0 million (2019), whereas its average is $9.0 million.
  • Data for Keros Therapeutics' Total Non-Current Liabilities shows a maximum YoY decreased of 25.93% (in 2020) over the last 5 years.
  • Keros Therapeutics' Total Non-Current Liabilities (Yearly) stood at $10.3 million in 2019, then decreased by 25.93% to $7.7 million in 2020.